Skip to main content
Psychedex

6Node page

what any key link opens

psx:substance/lsd/claim/47b37f6c-1fe7-4d26-b116-3eb81fd6c25e

claim2026-07-17recordpartially_supported

derived from · upstream

feeds · downstream

Closure of psx:substance/lsd/claim/47b37f6c-1fe7-4d26-b116-3eb81fd6c25e: 45 upstream, 111 downstream.

psx:substance/lsd/claim/47b37f6c-1fe7-4d26-b116-3eb81fd6c25e
├─ used  src/doi:10.1038/s41386-023-01607-2  Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants
  ├─ informed_by  claim/70e00ed9-4021-472d-a237-bcafa2896ac8  Claim in effects-overview — partially_supported
  ├─ informed_by  claim/a0b0a904-5265-4c37-86e3-e5794ae73a3a  Claim in effects-overview — supported
    ├─ used  src/doi:10.1124/pr.115.011478  Psychedelics
    ├─ used  src/doi:10.1038/s41386-020-00883-6  Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects
    ├─ used  src/doi:10.1016/j.cub.2016.02.010  Increased Global Functional Connectivity Correlates with LSD-Induced Ego Dissolution
    ├─ used  src/doi:10.1016/j.biopsych.2014.11.015  Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects
    ├─ used  src/doi:10.1073/pnas.1518377113  Neural correlates of the LSD experience revealed by multimodal neuroimaging
    ├─ used  src/doi:10.1111/bph.17361  Chemistry/structural biology of psychedelic drugs and their receptor(s)
    ├─ used  src/doi:10.1002/cpt.3726  Absolute Oral Bioavailability and Bioequivalence of LSD Base and Tartrate in a Double-Blind, Placebo-Controlled, Crossover Study
    ├─ used  src/doi:10.1016/j.cell.2020.08.024  Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor
    ├─ used  src/doi:10.1038/s41593-023-01316-5  Psychedelics promote plasticity by directly binding to BDNF receptor TrkB
    ├─ used  src/doi:10.1016/j.celrep.2018.05.022  Psychedelics Promote Structural and Functional Neural Plasticity
    ├─ used  src/doi:10.1007/s40262-017-0513-9  Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects
    ├─ used  src/doi:10.1002/cpt.2057  Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy Participants
    ├─ used  src/doi:10.1038/s41598-021-90343-y  Genetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis
    ├─ used  src/doi:10.1002/cpt.3618  Acute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre-Administration in a Randomized, Double-Blind, Cross-Over Phase I Trial
    ├─ used  src/doi:10.1016/j.biopsych.2022.08.025  Lysergic Acid Diethylamide-Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study
    ├─ used  src/doi:10.1192/bjp.2024.99  LSD-assisted therapy in patients with anxiety: open-label prospective 12-month follow-up
    ├─ used  src/doi:10.1177/0269881112439253  Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials
    ├─ used  src/doi:10.1016/j.pnpbp.2026.111645  LSD microdosing for major depressive disorder: Mood and pharmacokinetic outcomes from a Phase 2a trial
    ├─ used  src/doi:10.1177/0269881120940937  A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers
    ├─ used  src/doi:10.1038/s41386-022-01297-2  Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects
    ├─ used  src/doi:10.3389/fnhum.2014.00020  The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs
    ├─ used  src/doi:10.1038/s41398-024-03074-9  Pharmacological and non-pharmacological predictors of the LSD experience in healthy participants
    ├─ used  src/doi:10.1007/s00213-021-05978-6  Safety pharmacology of acute LSD administration in healthy subjects
    ├─ used  src/doi:10.1177/02698811231225609  Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins
    ├─ used  src/doi:10.1007/7854_2016_457  A Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPD
    ├─ used  src/doi:10.3390/brainsci8030047  Hallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic Perspectives
    ├─ used  src/doi:10.1007/s00213-022-06066-z  Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants
    ├─ used  src/doi:10.1097/HRP.0000000000000439
    ├─ used  src/doi:10.1038/s41380-024-02800-5  Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies
    ├─ used  src/pmid:38986146  New-Onset Seizures in an Adolescent Following Use of LSD while on Low-Dose Lithium Therapy: A Case Study
    ├─ used  src/url:2d4d277ba0208a82  Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures: an analysis of online psychedelic experience reports
    ├─ used  src/url:d1bbad71c868eacb
    ├─ used  src/url:8b469b5bfdb8789d
    ├─ used  src/url:d3fa34a898a1c047
    ├─ used  src/url:19dee37ed0b09c5c
    ├─ generated_by  pub/00599d13-ba7d-4297-9b8f-891432285be2  Publication — backfill
    ├─ invalidated_by  pub/0a6947c9-2333-4664-a19f-57c014faae3c  Publication — publish
      ├─ invalidated_by  issue/notice@f069a9dea47b  Issued notice
      ├─ invalidated_by  issue/info_card@ab88b29eebc8  Issued info_card
      ├─ invalidated_by  issue/emergency@c15c760aabf6  Issued emergency
      ├─ attributed_to  human/reviewer:Dev Bypass
      └─ invalidated_by  pub/422f95e7-5178-45dc-b74d-d27166557943  Publication — publish
├─ informed_by  section/effects-overview.full@1
  ├─ used  version/1  Revision 1
  ├─ used  claim/c4657c7b-25db-417e-afe5-35fc4d44b409  Claim in summary — supported
  ├─ used  claim/dc5feca7-8647-458c-b292-408db2b2e2bd  Claim in pharmacology — supported
  ├─ used  claim/e64e4909-739a-47c3-baf9-f596734b04aa  Claim in pharmacokinetic-detail — supported
  ├─ used  claim/adce01dc-bb57-4e66-840e-4fb77849a0d5  Claim in comparative-pharmacology — supported
  ├─ used  claim/550669c4-487c-4fd0-8def-b27f1150b323  Claim in comparative-pharmacology — supported
  ├─ used  claim/699bc9fc-4f9a-400c-8226-be876292aeac  Claim in effects-overview — partially_supported
  ├─ used  claim/594871d9-f229-4ca7-855a-da65543eb2ef  Claim in comparative-pharmacology — supported
  ├─ used  version/2  r1.a1
    ├─ derived_from  issue/notice@64878b43a1d2  Issued notice
    ├─ derived_from  issue/info_card@661b6d0eb350  Issued info_card
    ├─ derived_from  issue/emergency@3f0909c25c71  Issued emergency
    ├─ revised_from  version/3  r1.a2
    ├─ informed_by  section/summary.full@1
    ├─ informed_by  section/pharmacology.full@1
    ├─ informed_by  section/pharmacokinetic-detail.full@1
    ├─ informed_by  section/comparative-pharmacology.full@1
      ├─ used  claim/d51c5140-4789-4271-b26c-d179d731ebc0  Claim in summary — inconclusive  working
      ├─ used  claim/c1c27e4a-5a60-4b0b-9dd5-9c842eb329bf  Claim in summary — supported
      ├─ used  claim/14bd3d79-df8b-4b1d-8142-1f93f5149a36  Claim in history — inconclusive  working
      ├─ used  claim/6ea48958-f6b0-4e15-abd6-e5ff20b5f0b6  Claim in pharmacology — supported
      ├─ used  claim/3f5bf3b2-c2fd-4d2a-af86-7c0c46b46d49  Claim in pharmacology — inconclusive  working
      ├─ used  claim/ad88ce10-57e3-45dc-9406-b0b52adc559b  Claim in pharmacology — supported
      ├─ used  claim/06f683ea-6b6d-4dfd-93be-c4627393e8cc  Claim in safety — supported
      ├─ used  claim/a0c56aca-1a09-44cd-9437-bed4c51f85fd  Claim in safety — inconclusive  working
      ├─ used  claim/bcd69036-c654-4216-b22b-61645c5a4b5b  Claim in safety — inconclusive  working
      ├─ used  claim/50d1181d-c9bc-481e-8555-75deea54adbf  Claim in safety — supported
      ├─ used  claim/f84a6728-d59b-4ec3-8303-cfe4c3fba320  Claim in safety — supported
      ├─ used  claim/74f655db-c217-4ab0-8654-7ffe57f52bf8  Claim in history — inconclusive  working
      ├─ used  claim/e257bede-ab05-4568-8add-9caaf63c21d8  Claim in history — inconclusive  working
      ├─ used  claim/96700e24-2be9-438f-b8ee-a617aa2d9218  Claim in chemistry — inconclusive  working
      ├─ used  claim/8305487a-4924-433a-b0b4-643752a75a68  Claim in receptor-pharmacology — supported
      ├─ used  claim/2c71e862-defa-495c-b7cc-5b2bef889d2b  Claim in receptor-pharmacology — inconclusive  working
      ├─ used  claim/fc650b91-cbd3-499b-b871-be71996e53e3  Claim in receptor-pharmacology — inconclusive  working
      ├─ used  claim/9150d99a-4e1f-45a0-9440-baa282b90075  Claim in comparative-pharmacology — inconclusive  working
      ├─ used  claim/40afbea3-b4df-4125-894a-9dbbeb6b2bb3  Claim in summary — supported
      ├─ used  claim/26147dd9-2fab-4a3a-b57f-33f7561a125b  Claim in pharmacokinetic-detail — supported
      ├─ used  claim/0b1b1fec-11c7-4165-ad7c-a3e960bea238  Claim in pharmacology — supported
      ├─ used  claim/14e82e8e-d5d4-4d48-af0c-516ef8926d66  Claim in pharmacology — supported
      ├─ used  claim/7b0a1366-6b6b-49e2-8de9-778dd59f5a8c  Claim in pharmacokinetic-detail — partially_supported
      ├─ used  claim/162dabd6-a678-4626-bbb8-461fd984edb9  Claim in history — not_supported  working
      ├─ used  claim/596253d4-2b37-425b-95ba-3793e97d3f45  Claim in neuroscience — supported
      ├─ used  claim/d9f0ab36-38f8-4622-a678-671a91dedd1b  Claim in safety — inconclusive  working
      ├─ used  claim/d46014e9-158e-43fd-befa-3bea639593a4  Claim in safety — supported
      ├─ used  claim/7bc45e99-7cee-487b-ad31-94fdf911af0e  Claim in safety — inconclusive  working
      ├─ used  claim/c4d27f57-6549-4c0b-87a5-e961ca84d3e4  Claim in history — supported
      ├─ used  claim/92678bc7-286e-485e-8806-7385f2de1c36  Claim in neuroscience — supported
      ├─ used  claim/5734bf4e-10e2-4943-8756-d1b9b43358d6  Claim in neuroscience — partially_supported
      ├─ used  claim/b2a9b65c-66ce-419c-b636-e5aaf1490a9a  Claim in pharmacology — inconclusive  working
      ├─ used  claim/46b7ba61-2cdd-428d-9553-010de9d070e8  Claim in chemistry — supported
      ├─ used  claim/125a8d0a-2586-4bd9-b426-940f2d02a2d4  Claim in pharmacology — supported
      ├─ used  claim/e1266c66-5e7f-46fd-925c-8c21c439c081  Claim in pharmacology — supported
      ├─ used  claim/52194901-64d7-470c-a564-88c60624717f  Claim in pharmacokinetic-detail — supported
      ├─ used  claim/fc0eea34-d3fb-4739-a14a-7eee408030d2  Claim in pharmacokinetic-detail — supported
      ├─ used  claim/aeaa0b72-3d3a-4e1e-814b-d2003dc57bf3  Claim in pharmacology — not_supported  working
      ├─ used  claim/99a8be51-30ae-4b20-92c3-2f623e6fdeae  Claim in pharmacology — inconclusive  working
      ├─ used  claim/745a845b-3334-47a3-87cf-66ce1937e821  Claim in receptor-pharmacology — supported
      ├─ used  claim/2dd5401a-9331-477d-900c-e26f18b51947  Claim in receptor-pharmacology — partially_supported
      ├─ used  claim/d031f756-bd04-4ed5-be7e-e6a4d60fcf71  Claim in neuroscience — inconclusive  working
      ├─ used  claim/9ee0038b-505f-4c78-b995-3084f244a0f0  Claim in pharmacology — supported
      ├─ used  claim/4df80d17-a8a5-488f-8728-e9ca2cc31ba8  Claim in pharmacology — supported
      ├─ used  claim/f0068f50-bdde-487a-ad68-26fdbdb6f19f  Claim in receptor-pharmacology — supported
      ├─ used  claim/3aa38cc4-a142-4afb-8daa-26063b384c6b  Claim in neuroscience — supported
      ├─ used  claim/2a79fc7e-fbae-4538-9163-001d85a65dfe  Claim in neuroscience — supported
      ├─ used  claim/981c6ec1-e441-4b8c-911d-b1b8ad86dad0  Claim in pharmacology — supported
      ├─ used  claim/40c0c6e9-9115-4c93-b82f-d1700091a490  Claim in neuroscience — supported
      ├─ used  claim/23f21aae-4028-4e46-967d-6fe1e86c29c4  Claim in pharmacology — inconclusive  working
      ├─ used  claim/8509706e-9df1-41b0-b9b1-437369f14a8b  Claim in pharmacology — inconclusive  working
      ├─ used  claim/9669f285-78f7-4eb1-b474-090c2b30fc6a  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ used  claim/31ea507b-d6ee-42e5-adf0-7284083890a8  Claim in pharmacology — supported
      ├─ used  claim/80ca6f1a-e4a7-4486-bcba-a7f5bafb189e  Claim in pharmacology — supported
      ├─ used  claim/48952db4-f65c-482c-af1a-e320fffcb641  Claim in pharmacology — supported
      ├─ used  claim/72adbfc4-135c-4f88-9076-fbb45e4a58da  Claim in pharmacokinetic-detail — supported
      ├─ used  claim/7cfff8fb-032c-47c3-843f-e4af2d2ba8df  Claim in pharmacology — supported
      ├─ used  claim/496113cb-8192-424c-a42d-70cae694c3df  Claim in pharmacology — supported
      ├─ used  claim/d0232e03-05b0-4b8d-9d11-3ee9a6202504  Claim in pharmacology — supported
      ├─ used  claim/94cb4cf8-a227-4f3c-a058-ef878082eb5a  Claim in pharmacology — inconclusive  working
      ├─ used  claim/e0acc88b-81cd-45ad-8755-a17f170e3c5c  Claim in pharmacokinetic-detail — supported
      ├─ used  claim/015300eb-c901-4e95-b496-3a4b75aa0422  Claim in pharmacokinetic-detail — supported
      ├─ used  claim/4a8723e0-7cab-4afa-a25d-36b7b91bfe75  Claim in pharmacology — supported
      ├─ used  claim/956cb5f6-8a5f-466b-a44e-d573f782f56e  Claim in pharmacokinetic-detail — supported
      ├─ used  claim/776ebd74-7761-411e-8c38-69d8a6886f1f  Claim in pharmacokinetic-detail — supported
      ├─ used  claim/ac6d252e-e387-4bdf-9b48-26724ec998a6  Claim in safety — inconclusive  working
      ├─ used  claim/4099e7d8-89a3-47ed-92b5-d90002a8368d  Claim in safety — supported
      ├─ used  claim/d7a2a2d0-7f24-4bbc-a983-35ad4d4b223a  Claim in safety — supported
      ├─ used  claim/1359304d-d506-4504-a37a-19733c3d0319  Claim in clinical-evidence — supported
      ├─ used  claim/1a102400-4407-41ef-89b0-767cf985da2a  Claim in clinical-evidence — supported
      ├─ used  claim/b9310632-5a70-4847-a139-200ae917d582  Claim in clinical-evidence — supported
      ├─ used  claim/418db32f-e096-4edc-8636-e90f88a5bccd  Claim in comparative-pharmacology — partially_supported
      ├─ used  claim/6d9e7c9b-6ff3-4ee6-ad6b-84d50938a394  Claim in neuroscience — supported
      ├─ used  claim/b8693140-2669-4e7f-9ff2-493478557799  Claim in safety — supported
      ├─ used  claim/255feb78-d410-4c03-bbd6-e87634685914  Claim in safety — supported
      ├─ used  claim/57ea052f-815a-4d41-a5eb-4a2268f17092  Claim in safety — partially_supported
      ├─ used  claim/9165f74e-c90c-43ee-9f59-3d3ecc12cb3a  Claim in safety — supported
      ├─ used  claim/cb8d16c8-deb6-42bf-863a-790f65758987  Claim in safety — supported
      ├─ used  claim/01b62954-cec4-4248-ab77-25a28aa435e4  Claim in safety — inconclusive  working
      ├─ used  claim/87a2f43f-53cb-4a5b-92db-51fbaa46ae02  Claim in safety — inconclusive  working
      ├─ used  claim/db825e39-d037-4cb9-bed5-d584c7c05bbb  Claim in safety — supported
      ├─ used  claim/dd235e59-456b-4e0b-b203-bbd0c7a0afe1  Claim in safety — partially_supported
      ├─ used  claim/d3aab0b1-48b9-4975-8991-75b20426704f  Claim in safety — inconclusive  working
      ├─ used  claim/c681d219-cbe2-40b4-9ef7-f02b787b9d4d  Claim in safety — inconclusive  working
      ├─ used  claim/9ab0a884-7472-4e47-ba19-9d3bf848e052  Claim in safety — supported
      ├─ used  claim/cadea6ad-d25f-4d12-9b77-ca66610f1b84  Claim in safety — partially_supported
      ├─ used  claim/5d20b105-aaae-4efc-a3e0-a2858c142c7f  Claim in safety — partially_supported
      ├─ used  claim/04898c47-2c6d-45ee-b7ad-8e87de7765be  Claim in safety — partially_supported
      ├─ used  claim/f91478a7-3b3a-40a6-91da-6fc52fb5f5a5  Claim in safety — supported
      ├─ used  claim/5ccea188-24ac-402c-99bc-8c366aa78d5b  Claim in safety — inconclusive  working
      ├─ used  claim/9374fbf2-fe07-4057-8f31-9caeab9c674e  Claim in safety — supported
      ├─ used  claim/cb5694eb-9f77-41d9-b1a6-0f66ac563be2  Claim in safety — supported
      └─ revised_from  version/4  r1.a3
… closure truncated at 200 nodes

indented by distance from this node, not by parentage

1Provenance card

the boundary, as counts

Sources

3331 with DOI

26 strong · 6 moderate · 1 weak

Compilations

0no compilation run

16 other runs

Decisions

75last ruled 2026-10-03

32 awaiting a ruling

Issued documents

102026-10-19T20:32:32.507Z

notice · info card · emergency

Searches

00 with no results

queries and counts on the build

Claims checked

10274 supported

74 supported · 28 not

Correspondence

0received

consent field ships in Phase 4

Edges

341

derivations recorded for this entity

Complete over 33 sources and 75 decisions.Not here: the private journal (never); 32 proposals awaiting a ruling (listed as pending only).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/lsd/archive

2Build

one panel per compilation run

Other runs

  1. findings run2026-08-19failed15 min102 entriesrun/1c0ee90a…
  2. findings run2026-08-19failed15 minrun/9bfe8fae…
  3. findings run2026-08-19failed45 minrun/6b59a6a5…
  4. findings run2026-08-20completed29 minrun/bd5dfd79…
  5. brief run2026-09-18failed15 minrun/17d1cf3a…
  6. brief run2026-09-18failed23 minrun/174d8129…
  7. brief run2026-09-18completed15 minrun/277733d4…
  8. brief run2026-09-22completed4 minrun/3ab2c8cc…
  9. brief run2026-09-22completed5 minrun/cf82bfe4…
  10. brief run2026-09-23completed2 minrun/af0dca76…
  11. brief run2026-09-27completed3 minrun/74090ed1…
  12. brief run2026-09-27completed3 minrun/69f96ff8…
  13. brief run2026-09-27completed6 minrun/9c00cf4b…
  14. brief run2026-09-27completed4 minrun/2805f59c…
  15. brief run2026-09-27completed4 minrun/507aef3b…
  16. brief run2026-09-28completed3 minrun/a03fe9e2…

3Sources

32 consumed · sorted by year · feeds = sections resting on it

Sources 1 to 30
yearsourcetierstatusfeeds
2026LSD microdosing for major depressive disorder: Mood and pharmacokinetic outcomes from a Phase 2a trialDaldegan-Bueno D, Donegan CJ, Sumner R, Forsyth A, et al., Muthukumaraswamy S · Progress in Neuro-Psychopharmacology and Biological Psychiatrydoi:10.1016/j.pnpbp.2026.111645moderateconsumed1 section
2025Absolute Oral Bioavailability and Bioequivalence of LSD Base and Tartrate in a Double-Blind, Placebo-Controlled, Crossover StudyArikci D, Holze F, Mueller L, Vizeli P, Rudin D, Luethi D, Hysek CM, Liechti ME · Clinical Pharmacology and Therapeuticsdoi:10.1002/cpt.3726strongconsumed2 sections
2025Acute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre-Administration in a Randomized, Double-Blind, Cross-Over Phase I TrialBecker AM, Humbert-Droz M, Mueller L, Jelušić A, Tolev A, Straumann I, Avedisian I, Erne L, Thomann J, Luethi D, Grünblatt E, Meyer Zu Schwabedissen H, Liechti ME · Clinical Pharmacology and Therapeuticsdoi:10.1002/cpt.3618strongconsumed3 sections
2025Pharmacological Treatment of Hallucinogen Persisting Perception Disorder (HPPD): A Systematic ReviewNeven A, Blom JD · Harvard Review of Psychiatrydoi:10.1097/hrp.0000000000000439strongconsumedcited only
2025Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studiesSabé M, Sulstarova A, Glangetas A, De Pieri M, et al., Kirschner M · Molecular Psychiatrydoi:10.1038/s41380-024-02800-5strongconsumed1 section
2024Chemistry/structural biology of psychedelic drugs and their receptor(s)Gumpper RH, Nichols DE · British Journal of Pharmacologydoi:10.1111/bph.17361strongconsumed2 sections
2024LSD-assisted therapy in patients with anxiety: open-label prospective 12-month follow-upHolze F, Gasser P, Müller F, Strebel M, Liechti ME · British Journal of Psychiatrydoi:10.1192/bjp.2024.99moderateconsumed1 section
2024Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxinsRouaud A, Calder AE, Hasler G · Journal of Psychopharmacologydoi:10.1177/02698811231225609strongconsumed1 section
2024New-Onset Seizures in an Adolescent Following Use of LSD while on Low-Dose Lithium Therapy: A Case StudyEdwards C, Van Gerpen S, Anand V · South Dakota Medicinepmid:38986146moderateconsumed1 section
2024Pharmacological and non-pharmacological predictors of the LSD experience in healthy participantsVizeli P, Studerus E, Holze F, Schmid Y, Dolder PC, Ley L, Straumann I, Becker AM, Müller F, Arikci D, Liechti ME · Translational Psychiatrydoi:10.1038/s41398-024-03074-9strongconsumed1 section
2023Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participantsLey L, Holze F, Arikci D, Becker AM, Straumann I, Klaiber A, Coviello F, Dierbach S, Thomann J, Duthaler U, Luethi D, Varghese N, Eckert A, Liechti ME · Neuropsychopharmacologydoi:10.1038/s41386-023-01607-2strongconsumed5 sections
2023Lysergic Acid Diethylamide-Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II StudyHolze F, Gasser P, Müller F, Dolder PC, Liechti ME · Biological Psychiatrydoi:10.1016/j.biopsych.2022.08.025strongconsumed1 section
2023Psychedelics promote plasticity by directly binding to BDNF receptor TrkBMoliner R, Girych M, Brunello CA, Kovaleva V, Biojone C, Enkavi G, Antenucci L, Kot EF, Goncharuk SA, Kaurinkoski K, Kuutti M, Fred SM, Elsilä LV, Sakson S, Cannarozzo C, Diniz CRAF, Seiffert N, Rubiolo A, Haapaniemi H, Meshi E, Nagaeva E, Öhman T, Róg T, Kankuri E, Vilar M, Varjosalo M, Korpi ER, Permi P, Mineev KS, Saarma M, Vattulainen I, Casarotto PC, Castrén E · Nature Neurosciencedoi:10.1038/s41593-023-01316-5strongconsumed3 sections
2022Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjectsHolze F, Ley L, Müller F, Becker AM, Straumann I, Vizeli P, Kuehne SS, Roder MA, Duthaler U, Kolaczynska KE, Varghese N, Eckert A, Liechti ME · Neuropsychopharmacologydoi:10.1038/s41386-022-01297-2strongconsumed2 sections
2022Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participantsMüller F, Kraus E, Holze F, Becker A, Ley L, Schmid Y, Vizeli P, Liechti ME, Borgwardt S · Psychopharmacologydoi:10.1007/s00213-022-06066-zstrongconsumed1 section
2022Safety pharmacology of acute LSD administration in healthy subjectsHolze F, Caluori TV, Vizeli P, Liechti ME · Psychopharmacologydoi:10.1007/s00213-021-05978-6strongconsumed1 section
2021A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteersRamaekers JG, Hutten N, Mason NL, Dolder P, Theunissen EL, Holze F, Liechti ME, Feilding A, Kuypers KP · Journal of Psychopharmacologydoi:10.1177/0269881120940937strongconsumedcited only
2021Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjectsHolze F, Vizeli P, Müller F, Ley L, Duerig R, Varghese N, Zizzari P, Liechti ME · Neuropsychopharmacologydoi:10.1038/s41386-020-00883-6strongconsumed3 sections
2021Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures: an analysis of online psychedelic experience reportsJohnson MW, et al.url:2d4d277ba0208a82weakconsumedcited only
2021Genetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysisVizeli P, Straumann I, Holze F, Schmid Y, Dolder PC, Liechti ME · Scientific Reportsdoi:10.1038/s41598-021-90343-ystrongconsumed2 sections
2021Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy ParticipantsHolze F, Liechti ME, Hutten NRPW, Mason NL, Dolder PC, Theunissen EL, Duthaler U, Feilding A, Ramaekers JG, Kuypers KPC · Clinical Pharmacology and Therapeuticsdoi:10.1002/cpt.2057strongconsumed2 sections
2020Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin ReceptorKim K, Che T, Panova O, DiBerto JF, Lyu J, Krumm BE, Wacker D, Robertson MJ, Seven AB, Nichols DE, Shoichet BK, Skiniotis G, Roth BL · Celldoi:10.1016/j.cell.2020.08.024strongconsumed3 sections
2018A Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPDHalpern JH, Lerner AG, Passie T · Current Topics in Behavioral Neurosciencesdoi:10.1007/7854_2016_457moderateconsumed1 section
2018Hallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic PerspectivesMartinotti G, Santacroce R, Pettorruso M, Montemitro C, Spano MC, Lorusso M, Di Giannantonio M, Gallimberti L · Brain Sciencesdoi:10.3390/brainsci8030047moderateconsumed1 section
2018Psychedelics Promote Structural and Functional Neural PlasticityLy C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, Burbach KF, Soltanzadeh Zarandi S, Sood A, Paddy MR, Duim WC, Dennis MY, McAllister AK, Ori-McKenney KM, Gray JA, Olson DE · Cell Reportsdoi:10.1016/j.celrep.2018.05.022strongconsumed2 sections
2017Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy SubjectsDolder PC, Schmid Y, Steuer AE, Kraemer T, Rentsch KM, Hammann F, Liechti ME · Clinical Pharmacokineticsdoi:10.1007/s40262-017-0513-9strongconsumed2 sections
2016Increased Global Functional Connectivity Correlates with LSD-Induced Ego DissolutionTagliazucchi E, Roseman L, Kaelen M, Orban C, Muthukumaraswamy SD, Murphy K, Laufs H, Leech R, McGonigle J, Crossley N, Bullmore E, Williams T, Bolstridge M, Feilding A, Nutt DJ, Carhart-Harris R · Current Biologydoi:10.1016/j.cub.2016.02.010strongconsumed2 sections
2016Neural correlates of the LSD experience revealed by multimodal neuroimagingCarhart-Harris RL, Muthukumaraswamy S, Roseman L, Kaelen M, Droog W, Murphy K, Tagliazucchi E, Schenberg EE, Nest T, Orban C, Leech R, Williams LT, Williams TM, Bolstridge M, Sessa B, McGonigle J, Sereno MI, Nichols D, Hellyer PJ, Hobden P, Evans J, Singh KD, Wise RG, Curran HV, Feilding A, Nutt DJ · Proceedings of the National Academy of Sciencesdoi:10.1073/pnas.1518377113strongconsumed1 section
2016PsychedelicsNichols DE · Pharmacological Reviewsdoi:10.1124/pr.115.011478strongconsumed7 sections
2015Acute Effects of Lysergic Acid Diethylamide in Healthy SubjectsSchmid Y, Enzler F, Gasser P, Grouzmann E, Preller KH, Vollenweider FX, Brenneisen R, Müller F, Borgwardt S, Liechti ME · Biological Psychiatrydoi:10.1016/j.biopsych.2014.11.015strongconsumed2 sections
Show all 33 sources — 3 more
Sources 31 to 33
yearsourcetierstatusfeeds
2014The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugsCarhart-Harris RL, Leech R, Hellyer PJ, Shanahan M, Feilding A, Tagliazucchi E, Chialvo DR, Nutt D · Frontiers in Human Neurosciencedoi:10.3389/fnhum.2014.00020strongconsumed1 section
2012Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trialsKrebs TS, Johansen PØ · Journal of Psychopharmacologydoi:10.1177/0269881112439253strongconsumedcited only
—Crystal Structure of an LSD-Bound Human Serotonin Receptordoi:10.1016/j.cell.2016.12.033—unknowncited only

4Docket

one filing per activity — decisions, correspondence, reports

awaiting ruling — 32

  • safety_finding · oral · toxicity · safety_margincited2026-08-20
  • safety_finding · toxicity · mortality_record2026-08-20
  • safety_finding · toxicity · adulterant_hazard2026-08-20
  • safety_finding · toxicity · acute_toxicitycited2026-08-20
  • safety_finding · toxicity · cardiovascularcited2026-08-20
  • safety_finding · toxicity · cardiovascularcited2026-08-20
  • safety_finding · toxicity · receptor_concern2026-08-20
  • safety_finding · toxicity · cardiovascular2026-08-20
  • safety_finding · toxicity · study_safetycited2026-08-20
  • safety_finding · toxicity · study_safetycited2026-08-20
  • safety_finding · psychological_risks · hppd2026-08-20
  • safety_finding · psychological_risks · hppd2026-08-20
  • safety_finding · psychological_risks · hppd2026-08-20
  • safety_finding · psychological_risks · hppdcited2026-08-20
  • safety_finding · psychological_risks · hppd2026-08-20
  • safety_finding · psychological_risks · psychosiscited2026-08-20
  • safety_finding · psychological_risks · psychosiscited2026-08-20
  • safety_finding · psychological_risks · psychosis2026-08-20
  • safety_finding · toxicity · serotonergic2026-08-20
  • safety_finding · toxicity · serotonergic2026-08-20
  • safety_finding · toxicity · neurological2026-08-20
  • safety_finding · toxicity · neurologicalcited2026-08-20
  • safety_finding · toxicity · neurologicalcited2026-08-20
  • safety_finding · toxicity · neurologicalcited2026-08-20
  • safety_finding · toxicity · serotonergic2026-08-20
  • safety_finding · oral · toxicity · serotonergiccited2026-08-20
  • safety_finding · oral · toxicity · study_safetycited2026-08-20
  • safety_finding · toxicity · serotonergic2026-08-20
  • safety_finding · toxicity · serotonergic2026-08-20
  • safety_finding · toxicity · reproductive2026-08-20
  • safety_finding · toxicity · neurological2026-08-20
  • safety_finding · toxicity · cardiovascular2026-08-20
  1. 0012026-04-19revisionRevision 1

    Initial LLM generation (v5 pipeline, wiki)

    psx:substance/lsd/version/1
  2. 0022026-06-04proposal30 value proposals approved together

    one review action inferred from a shared reviewer and instant — the graph records one activity per proposal

    30 items in this filing

    • dose_tier · light
    • dose_tier · common
    • dose_tier · strong
    • dose_tier · heavy
    • timeline · oral · onset
    • timeline · oral · come_up
    • timeline · oral · ascent
    • timeline · oral · peak
    • timeline · oral · plateau
    • timeline · oral · resolution
    • timeline · oral · afterglow
    • toxicity
    • dependence · full
    • withdrawal
    • tolerance
    • dosage · oral
    • duration · oral · onset
    • duration · oral · come_up
    • duration · oral · peak
    • duration · oral · offset
    • duration · oral · total
    • duration · oral · aftereffects
    • contraindication · psychiatric
    • contraindication · psychiatric
    • contraindication · neurological
    • contraindication · other
    • contraindication · cardiovascular
    • contraindication · pregnancy_breastfeeding
    • contraindication · other
    psx:substance/lsd/proposal/dose_tier/d6efb877-0f42-4a97-9d6f-87b5494be767
  3. 0032026-06-04publicationPublication — backfill
    psx:substance/lsd/pub/00599d13-ba7d-4297-9b8f-891432285be2
  4. 0042026-08-24revisionr1.a1

    technical error

    psx:substance/lsd/version/2
  5. 0052026-09-20revisionr1.a2

    no edit summary recorded

    psx:substance/lsd/version/3
  6. 0062026-09-20publicationPublication — publishagent-psx (local dev)
    psx:substance/lsd/pub/0a6947c9-2333-4664-a19f-57c014faae3c
  7. 0072026-09-22revisionr1.a3

    no edit summary recorded

    psx:substance/lsd/version/4
  8. 0082026-09-23publicationPublication — publishChris
    psx:substance/lsd/pub/422f95e7-5178-45dc-b74d-d27166557943
  9. 0092026-09-23revisionr1.a4

    no edit summary recorded

    psx:substance/lsd/version/5
  10. 0102026-09-24publicationPublication — publishagent-psx (local dev)
    psx:substance/lsd/pub/ac271cc8-474f-4a8f-aabc-da71153b8db7
  11. 0112026-09-27revisionr1.a5

    brief-overview retired 2026-09-30 (founder): Description reads the essential summary for every substance.

    psx:substance/lsd/version/6
  12. 0122026-10-03revisionr1.a6

    Restore reagent testing, appearance and the identification guide carried by r1. They were dropped when amendment r1.a2 was created on 2026-09-20: the amendment copier carried only the summary columns (fixed 7d6e6ade8). Values copied unchanged from r1.

    psx:substance/lsd/version/7
  13. 0132026-10-03publicationPublication — publishagent-psx
    psx:substance/lsd/pub/129688e3-a57d-44b1-9968-d7197c942c5e
  14. 0142026-10-03revisionr1.a7

    no edit summary recorded

    psx:substance/lsd/version/8

5Issued documents

what the notice, info card and emergency page said, by hash

Issued documents
documentcontent hashissuedfrom versionsuperseded
emergencyc15c760aabf6f0fcf5b6fc6b…2026-10-19 20:32Revision 7current
info_carda8d971188c3ca510a5c975fe…2026-10-19 20:32Revision 7current
info_card4c6647f545c338ee3cbb4a63…2026-10-03 21:31Revision 7superseded2026-10-19
info_card5663c86ee3b8f14c6bfbe8f8…2026-09-24 10:06Revision 5superseded2026-10-03
info_card2a2db6475e85b8efd25000be…2026-09-23 07:47Revision 4superseded2026-09-24
noticef069a9dea47b308467344618…2026-09-23 07:47Revision 4current
info_cardab88b29eebc8cacc6ecfe7af…2026-09-20 08:15Revision 3superseded2026-09-23
emergency3f0909c25c714d225b4bb3e3…2026-09-04 04:30Revision 1superseded2026-10-19
info_card661b6d0eb350b1e2bb2cc63c…2026-09-04 04:30Revision 1superseded2026-09-20
notice64878b43a1d2932a5305f55b…2026-09-04 04:30Revision 1superseded2026-09-23